Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Venditti

Showing results (51-60 of 100) with videos related to

Pageof 10
Sort By:
Circulation|August 1, 1994
Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart StudyH Tsuji, F J Venditti, E S Manders, et al.
Progress in Clinical and Biological Research|January 1, 1986
Pleiotropic resistance and drug developmentR Shoemaker, M Wolpert-DeFilippes, J Plowman, et al.
Circulation|December 1, 1996
Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart StudyH Tsuji, M G Larson, F J Venditti, et al.
Critical Reviews in Toxicology|May 12, 2015
Ozone exposure and systemic biomarkers: Evaluation of evidence for adverse cardiovascular health impactsJulie E Goodman, Robyn L Prueitt, Sonja N Sax, et al.
JAMA Network Open|December 18, 2020
Effect of a Culturally Adapted Behavioral Intervention for Latino Adults on Weight Loss Over 2 Years: A Randomized Clinical TrialLisa G Rosas, Nan Lv, Lan Xiao, et al.
The Journal of Thoracic and Cardiovascular Surgery|June 1, 1995
Transvenous versus transthoracic cardioverter-defibrillator implantation. A comparative analysis of morbidity, mortality, and survivalD M Shahian, W A Williamson, L G Svensson, et al.
The American Journal of Cardiology|July 1, 1989
Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarctsD L Kuchar, H Garan, F J Venditti, et al.
Circulation|September 1, 1995
Morning peak in ventricular tachyarrhythmias detected by time of implantable cardioverter/defibrillator therapy. The CPI InvestigatorsG H Tofler, O C Gebara, M A Mittleman, et al.
Cardiovascular Drugs and Therapy|January 14, 2022
A Clinical Perspective on Arsenic Exposure and Development of Atherosclerotic Cardiovascular DiseaseGurleen Kaur, Karan P Desai, Isabella Y Chang, et al.
Cardiovascular Drugs and Therapy|June 6, 2019
Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019Lane Zhang, David A Steckman, Evan C Adelstein, et al.
Pageof 10

Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Circulation|August 1, 1994
Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart StudyH Tsuji, F J Venditti, E S Manders, et al.
Progress in Clinical and Biological Research|January 1, 1986
Pleiotropic resistance and drug developmentR Shoemaker, M Wolpert-DeFilippes, J Plowman, et al.
Circulation|December 1, 1996
Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart StudyH Tsuji, M G Larson, F J Venditti, et al.
Critical Reviews in Toxicology|May 12, 2015
Ozone exposure and systemic biomarkers: Evaluation of evidence for adverse cardiovascular health impactsJulie E Goodman, Robyn L Prueitt, Sonja N Sax, et al.
JAMA Network Open|December 18, 2020
Effect of a Culturally Adapted Behavioral Intervention for Latino Adults on Weight Loss Over 2 Years: A Randomized Clinical TrialLisa G Rosas, Nan Lv, Lan Xiao, et al.
The Journal of Thoracic and Cardiovascular Surgery|June 1, 1995
Transvenous versus transthoracic cardioverter-defibrillator implantation. A comparative analysis of morbidity, mortality, and survivalD M Shahian, W A Williamson, L G Svensson, et al.
The American Journal of Cardiology|July 1, 1989
Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarctsD L Kuchar, H Garan, F J Venditti, et al.
Circulation|September 1, 1995
Morning peak in ventricular tachyarrhythmias detected by time of implantable cardioverter/defibrillator therapy. The CPI InvestigatorsG H Tofler, O C Gebara, M A Mittleman, et al.
Cardiovascular Drugs and Therapy|January 14, 2022
A Clinical Perspective on Arsenic Exposure and Development of Atherosclerotic Cardiovascular DiseaseGurleen Kaur, Karan P Desai, Isabella Y Chang, et al.
Cardiovascular Drugs and Therapy|June 6, 2019
Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019Lane Zhang, David A Steckman, Evan C Adelstein, et al.
Pageof 10